Among the homogeneous neoplasms, there are major changes that impact how these cases should be evaluated and diagnosed that have significant therapeutic effects as well as being of biologic interest [1]. Non-Hodgkin lymphoma (NHL) is the fourth most common malignancy in children [2]. It is not considered to be a hereditary disorder, but the occurrence of NHL lymphoma in the same family is called familial NHL [3]. Pediatric NHL shows important differences in the distribution of histologic subtypes to NHL observed in adults who have clinical characteristics represented by almost exclusively diffuse high-grade lymphomas and frequent extranodal involvement [2]. The prognosis for children with non-Hodgkin lymphoma has been improving over the last two decades